Merck Presents Phase 3 CORALreef AddOn Data for Enlicitide, Highlighting Strong LDL-C Reductions and Potential as First Oral PCSK9 Inhibitor Merck has unveiled compelling late-breaking results from its Phase 3…
LEO Pharma Showcases New Real-World Data on Tralokinumab at AAD 2026, Highlighting Benefits Across Diverse Atopic Dermatitis Populations LEO Pharma has presented new post-hoc analyses from its ongoing TRACE study,…
Alnylam Highlights New Cardiovascular Data at ACC.26, Reinforcing Potential of RNAi Therapies in ATTR-CM and Hypertension Alnylam Pharmaceuticals has unveiled a comprehensive set of new clinical and real-world findings from…
Meiji Seika Pharma Invests in Centivax to Advance Universal Vaccine Innovation and Broaden Global Infectious Disease Preparedness Meiji Seika Pharma Co., Ltd., a leading Japanese pharmaceutical company with a long-standing…
Biocytogen Enters Platform Licensing Agreement with Taisho to Expand Use of RenNano® Antibody Discovery Technology Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a global biotechnology company recognized for its innovation in antibody-based…
PepGen Reports Encouraging Phase 2 Data for PGN-EDODM1 in Myotonic Dystrophy Type 1, Advances Higher-Dose Cohort in FREEDOM2 Trial PepGen Inc., a clinical-stage biotechnology company focused on advancing next-generation oligonucleotide…
DiaMedica Therapeutics Reports 2025 Financial Results and Advances Clinical Pipeline in Preeclampsia and Acute Ischemic Stroke DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for serious…
Emmaus Life Sciences Announces Annual Financial Performance Update Emmaus Life Sciences Reports 2025 Financial Results, Navigates Revenue Pressure with Cost Discipline and Strategic Shift Emmaus Life Sciences, Inc., a commercial-stage…
Roche Launches cobas MPX-E, a 4-in-1 Donor Screening Assay to Strengthen Global Blood Supply Safety Roche has announced the availability of its cobas® MPX-E assay, a next-generation qualitative in vitro…
Incyte Reports Positive 54-Week Late-Breaking Povorcitinib Data in Hidradenitis Suppurativa at AAD 2026 Incyte has reported new long-term findings from its pivotal Phase 3 STOP-HS clinical development program, highlighting the…
Bristol Myers Squibb Reports Positive Phase 3 SCOUT-HCM Results for Camzyos in Adolescents with Symptomatic oHCM Bristol Myers Squibb has announced compelling results from its pivotal Phase 3 SCOUT-HCM clinical…
Phase 2 CADENCE Trial Shows Positive Results, Establishing WINREVAIR™ as a Proof-of-Concept Therapy in CpcPH and HFpEF Merck & Co.—known as MSD outside the United States and Canada—has unveiled comprehensive…